Rovalpituzumab tesirine - Stemcentrx

Drug Profile

Rovalpituzumab tesirine - Stemcentrx

Alternative Names: Rova-T; SC16LD6.5

Latest Information Update: 10 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stemcentrx
  • Developer Bristol-Myers Squibb; Stemcentrx
  • Class Antineoplastics; Benzodiazepines; Immunoconjugates; Monoclonal antibodies; Pyrroles
  • Mechanism of Action DLL3 protein inhibitors; DNA modulators; DNA-damage-stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 12 Sep 2018 Stemcentrx completes a phase I trial for Small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02874664)
  • 10 Sep 2018 AbbVie initiates a phase-II long-term, extension study in Small cell lung cancer and Solid tumours in USA (IV) (NCT03543358)
  • 20 Aug 2018 AbbVie completes a phase I trial for Small cell lung cancer (Late-stage disease, Second-line therapy or greater, Recurrent) in Japan (NCT03086239)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top